quinazolines has been researched along with Myeloproliferative Disorders in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.17) | 18.7374 |
| 1990's | 6 (13.04) | 18.2507 |
| 2000's | 23 (50.00) | 29.6817 |
| 2010's | 15 (32.61) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Krečak, I; Lucijanić, M | 1 |
| Usui, N | 1 |
| Cervinek, L; Dulíček, P; Kissová, J; Ovesná, P; Pavlík, T; Penka, M; Pospíšilová, D; Schwarz, J | 1 |
| Ahn, IE; Natelson, E; Rice, L | 1 |
| Kim, YS; Lee, SH | 1 |
| De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A | 1 |
| Bourkova, L; Bulikova, A; Kissova, J; Ovesna, P; Penka, M | 1 |
| Bergmann, F; Griesshammer, M; Koschmieder, S; Kreher, S; Matzdorff, A; Ochsenreither, S; Pabinger, I; Petrides, PE; Riess, H; Tiede, A; Trappe, RU | 1 |
| Aksu, S; Büyükaşık, Y; Eliaçık, E; Göker, H; Haznedaroğlu, İC; Işık, A; Özcebe, OI; Sayınalp, N; Üner, A | 1 |
| Antelo, ML; de Las Heras, N; Gonzalez Porras, JR; Kerguelen, A; Raya, JM | 1 |
| Akay, OM; Andıç, N; Bolaman, AZ; Kadıköylü, VG; Ünübol, M; Yağcı, E; Yavaşoğlu, İ | 1 |
| Birgegård, G | 2 |
| Demeter, J; Dombi, P; Egyed, M; Homor, L; Illés, Á; Karádi, É; Kellner, Á; Simon, Z; Udvardy, M | 1 |
| D'adda, M; Drera, M; Ferrari, S; Micheletti, M; Rossi, G | 1 |
| Emadi, A; Spivak, JL | 1 |
| de Stricker, K; Hasselbalch, HC; Larsen, TS; Møller, MB; Pallisgaard, N | 1 |
| Gisslinger, H; Krumpl, G; Linkesch, W; Petrides, PE; Schüller, A; Steurer, M; Widmann, R | 1 |
| Bodzásová, C; Brychtová, Y; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Indrák, K; Jelínková, P; Jonásová, A; Kissová, J; Korístek, Z; Nováková, L; Pavlík, T; Penka, M; Pospísilová, D; Schutzová, M; Schwarz, J; Segethová, J; Voglová, J; Vozobulová, V; Walterová, L | 1 |
| Vannucchi, AM | 1 |
| He, XM; Li, Y; Zhang, LY | 1 |
| Andreasson, B; Birgegård, G; Björkholm, M; Ejerblad, E; Kvasnicka, HM; Löfvenberg, E; Markevärn, B; Merup, M; Nilssson, L; Palmblad, J; Samuelsson, J; Thiele, J | 1 |
| Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J | 1 |
| Albitar, M; Colburn, DE; Cortes, JE; Giles, FJ; Kantarjian, HM; O'Brien, SM; Tsimberidou, AM; Verstovsek, S; Welch, MA | 1 |
| Brunnbauer, K; Fuchs, N; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J; Volkwein, N | 1 |
| Birgegård, G; Björkholm, M; Kutti, J; Lärfars, G; Löfvenberg, E; Markevärn, B; Mauritzson, N; Merup, M; Palmblad, J; Samuelsson, J; Westin, J | 1 |
| Campbell, PJ; Curtin, N; Green, AR; Vassiliou, GS | 1 |
| Fruchtman, SM | 1 |
| Gastl, G; Gisslinger, H; Jedrzejczak, WW; Lin, W; Pytlik, R; Schlögl, E; Steurer, M | 1 |
| Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Mourits-Andersen, T; Nielsen, OJ; Penninga, E | 1 |
| Fiddler, G; Fruchtman, SM; Gilbert, HS; Lyne, A; Petitt, RM | 1 |
| Fruchtman, S | 1 |
| Harrison, CN | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T; Penttilä, K | 1 |
| Belada, D; Brychtová, Y; Bubeník, B; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Kissová, J; Lhot'anová, T; Micaníková, M; Penka, M; Pytlík, R; Schutzová, M; Schwarz, J; Seghetová, J; Siroký, O; Szotkowski, T; Voglová, J; Volková, Z; Vozobulová, V; Vránová, M | 1 |
| Giles, F; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S | 1 |
| Brychtová, Y; Bubeník, B; Cerná, O; Doubek, M; Dulícek, P; Dusek, L; Hadacová, I; Hlusí, A; Hochová, I; Kissová, J; Lhotanová, T; Micaníková, M; Pavlík, T; Penka, M; Pospísilová, D; Pytlík, R; Schützová, M; Schwarz, J; Seghetová, J; Szotkowski, T; Voglová, J; Volková, Z; Vozobulová, V; Vránová, M; Zapletal, O | 1 |
| Adachi, S; Endo, M; Ito, E; Kanegane, H; Kanezaki, R; Kiyoi, H; Kojima, S; Mano, H; Migita, M; Miura, M; Morinaga, S; Nakano, T; Sato, T; Terui, K; Toki, T; Xu, G | 1 |
| Mughal, TI | 1 |
| Hołub, A; Robak, T; Treliński, J | 1 |
| Mesa, RA; Petitt, RM; Silverstein, MN; Solberg, LA; Tefferi, A | 1 |
| Sréter, L | 1 |
| Adam, H; Burkhard, R; Honegger, HP; Widmer, L | 1 |
| Bennett, M | 1 |
| Lindley, C; Pescatore, SL | 1 |
| Fleming, JS; Knight, RC; Petitt, RM; Schacter, LP; Silverstein, MN; Solberg, LA | 1 |
15 review(s) available for quinazolines and Myeloproliferative Disorders
| Article | Year |
|---|---|
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Female; Fibrosis; Humans; Hydroxyurea; Janus Kinase 2; Leukapheresis; Middle Aged; Myeloproliferative Disorders; Nitriles; Phlebotomy; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Splenectomy; Splenomegaly | 2015 |
Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.
Topics: Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Male; Myeloproliferative Disorders; Quinazolines | 2015 |
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Topics: Age Factors; Bone Marrow; Cardiovascular Diseases; Humans; Interferon-alpha; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Tachycardia; Thrombocythemia, Essential | 2016 |
Anagrelide: 20 years later.
Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 2009 |
JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Incidence; Interferon-alpha; Janus Kinase 2; Multicenter Studies as Topic; Mutation, Missense; Myeloproliferative Disorders; Phenotype; Point Mutation; Quinazolines; Thrombophilia; Thrombosis | 2010 |
Management of the myeloproliferative disorders : distinguishing data from dogma.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombophilia | 2004 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals | 2004 |
Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
Topics: Animals; Fibrinolytic Agents; Humans; Myeloproliferative Disorders; Quinazolines; Thrombocytosis | 2005 |
Anagrelide treatment in myeloproliferative disorders.
Topics: Blood Platelets; Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines | 2006 |
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Myeloproliferative Disorders; Philadelphia Chromosome; Quinazolines | 2006 |
Primary thrombocythemia: a current perspective.
Topics: Aspirin; Diagnosis, Differential; Humans; Hydroxyurea; Interferon Type I; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Recombinant Proteins; Thrombocytosis | 1995 |
[Anagrelide--new antiplatelet drug].
Topics: Animals; Chronic Disease; Humans; Megakaryocytes; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines | 1994 |
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Topics: Animals; Bone Marrow; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Hematopoiesis; Hemodynamics; Humans; Megakaryocytes; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombosis | 1997 |
[Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1999 |
Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
Topics: Clinical Trials as Topic; Drug Approval; Fibrinolytic Agents; Humans; Myeloproliferative Disorders; Quinazolines; United States; United States Food and Drug Administration | 2000 |
7 trial(s) available for quinazolines and Myeloproliferative Disorders
| Article | Year |
|---|---|
Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Chromatography, High Pressure Liquid; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Randomized Controlled Trials as Topic; Solubility; Therapeutic Equivalency; Thrombocytosis; Young Adult | 2009 |
[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2009 |
Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.
Topics: Adult; Aged; Cohort Studies; Drug Administration Schedule; Follow-Up Studies; Humans; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Quinazolines; World Health Organization | 2013 |
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Topics: Adult; Aged; Chronic Disease; Diarrhea; Dose-Response Relationship, Drug; Female; Headache; Heart Rate; Humans; Male; Middle Aged; Myeloproliferative Disorders; Nausea; Patient Compliance; Patient Dropouts; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thrombocytosis | 2004 |
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Count; Quinazolines; Thrombocytosis; Treatment Outcome | 2004 |
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Topics: Adult; Aged; Anemia; Chronic Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocytosis; Thromboembolism; Treatment Outcome | 2004 |
[The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
Topics: Administration, Oral; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Finland; Follow-Up Studies; Humans; Male; Myeloproliferative Disorders; Prospective Studies; Quinazolines; Risk Assessment; Thrombocytosis; Treatment Outcome | 2006 |
24 other study(ies) available for quinazolines and Myeloproliferative Disorders
| Article | Year |
|---|---|
Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms.
Topics: Humans; Hydroxyurea; Kidney Function Tests; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2021 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk | 2017 |
[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with othe
Topics: Adult; Aged; Czech Republic; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Myeloproliferative Disorders; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis | 2013 |
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Polycythemia Vera; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis | 2013 |
Reversible dilated cardiomyopathy associated with long-term anagrelide therapy in a patient with chronic myeloproliferative disease: a serial 2-dimensional speckle tracking echocardiographic study.
Topics: Aged; Cardiomyopathy, Dilated; Drug Administration Schedule; Echocardiography; Humans; Male; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines | 2014 |
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome | 2015 |
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
Topics: Adult; Aged; Blood Platelets; Case-Control Studies; Female; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Male; Mean Platelet Volume; Middle Aged; Mutation; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Thrombosis | 2014 |
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo
Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Incidence; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myeloproliferative Disorders; Phlebotomy; Platelet Aggregation Inhibitors; Postoperative Complications; Pregnancy; Pregnancy Complications, Hematologic; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention; Thrombophilia; Venous Thromboembolism; von Willebrand Diseases | 2014 |
Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Hemorrhage; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Quinazolines; Retrospective Studies; Risk Factors; Turkey; Venous Thromboembolism; Young Adult | 2016 |
[An audit of the Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the essential thrombocythaemic patients].
Topics: Female; Humans; Hungary; Male; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Registries | 2017 |
The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
Topics: Adult; Aged; Blood Platelets; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Female; Hemoglobins; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Quinazolines; Retrospective Studies; Thrombocytosis | 2008 |
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Topics: Alleles; Chronic Disease; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Mutation; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2009 |
[Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Janus Kinase 2; Lapatinib; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
Topics: Blood Platelets; Chronic Disease; Fibrinolytic Agents; Humans; Megakaryocytes; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Proliferating Cell Nuclear Antigen; Quinazolines; Reference Values; Retrospective Studies; Thrombocytosis; Thrombopoiesis | 2002 |
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fibrinolytic Agents; Humans; Imatinib Mesylate; Male; Medical Records Systems, Computerized; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinazolines; Retrospective Studies; Survival Analysis | 2003 |
Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Topics: Adult; Aged; Biopsy; Blood Platelets; Bone Marrow; Chronic Disease; Drug Evaluation; Humans; Immunohistochemistry; Middle Aged; Myeloproliferative Disorders; Platelet Count; Quinazolines; Retrospective Studies; Thrombocytosis | 2003 |
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Safety; Time Factors | 2005 |
New approaches to the treatment of thrombocytosis.
Topics: Humans; Hydroxyurea; Interferon-alpha; Myeloproliferative Disorders; Platelet Count; Quinazolines; Thrombocytosis | 2003 |
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Topics: Humans; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 2006 |
[Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
Topics: Adult; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocytosis | 2007 |
Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Topics: Base Sequence; Cell Proliferation; Dose-Response Relationship, Drug; Down Syndrome; Female; Humans; Janus Kinase 3; Leukemia, Megakaryoblastic, Acute; Male; Molecular Sequence Data; Mutation; Myeloproliferative Disorders; Neoplasm Proteins; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2008 |
[Chronic myeloproliferative diseases].
Topics: Chronic Disease; Female; Fibrinolytic Agents; Humans; Interferons; Leukemia, Myeloid; Male; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential | 1998 |
[Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis; Treatment Outcome | 1998 |
Anagrelide: a new drug for treating thrombocytosis.
Topics: Adult; Aged; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Platelet Count; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential; Thrombocytosis | 1988 |